CORMEDIX INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- CORMEDIX INC. stock issued during period, value, new issues for the quarter ending 2025-12-31 was -$600.00, a 100.01% decline year-over-year.
- CORMEDIX INC. stock issued during period, value, new issues for the quarter ending 2025-09-30 was $3.89K, a 99.97% decline year-over-year.
- CORMEDIX INC. stock issued during period, value, new issues for the quarter ending 2025-06-30 was $82.37M, a 8058.38% increase year-over-year.
- CORMEDIX INC. stock issued during period, value, new issues for the quarter ending 2025-03-31 was $6.76M.
- CORMEDIX INC. stock issued during period, value, new issues for fiscal 2025 was $82.37M, a 336.25% increase from fiscal 2024.
- CORMEDIX INC. stock issued during period, value, new issues for fiscal 2024 was $18.88M, a 45.81% increase from fiscal 2023.
- CORMEDIX INC. stock issued during period, value, new issues for fiscal 2023 was $12.95M, a 27.13% decline from fiscal 2022.
- CORMEDIX INC. stock issued during period, value, new issues for fiscal 2022 was $17.77M, a 57.14% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2025-12-31 | -$600.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $82.37M 10-K · filed 2026-03-05 |
| 2025-09-30 | $3.89K 10-Q · filed 2025-11-12 | $94.64M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $82.37M 10-Q · filed 2026-08-13 | $107.00M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $6.76M 10-Q · filed 2025-05-06 | $25.64M derived: sum of 4 quarters · filed 2025-05-06 |
| 2024-12-31 | $5.51M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $18.88M 10-K · filed 2025-03-25 |
| 2024-09-30 | $12.37M 10-Q · filed 2024-10-30 | $13.81M derived: sum of 4 quarters · filed 2025-03-25 |
| 2024-06-30 | $1.01M 10-Q · filed 2024-08-14 | $44.32M derived: sum of 4 quarters · filed 2025-03-25 |
| 2024-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2025-03-25 | $48.63M derived: sum of 4 quarters · filed 2025-03-25 |
| 2023-12-31 | $433.90K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $12.95M 10-K · filed 2025-03-25 |
| 2023-09-30 | $42.88M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $5.31M 10-Q · filed 2024-08-14 | |
| 2022-12-31 | $6.05M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $17.77M 10-K · filed 2023-03-30 |
| 2022-09-30 | $308.67K 10-Q · filed 2022-11-10 | $11.72M derived: sum of 4 quarters · filed 2023-03-30 |
| 2022-06-30 | $8.41M 10-Q · filed 2022-08-11 | $11.42M derived: sum of 4 quarters · filed 2023-03-30 |
| 2022-03-31 | $3.00M 10-Q · filed 2022-05-12 | $3.00M derived: sum of 4 quarters · filed 2023-03-30 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $41.46M 10-K · filed 2023-03-30 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $56.84M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $57.47M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $41.46M 10-Q · filed 2022-05-12 | $57.47M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $15.39M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $18.43M 10-K · filed 2022-03-29 |
| 2020-09-30 | $622.82K 10-Q · filed 2020-11-05 | $3.09M derived: sum of 4 quarters · filed 2021-05-13 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $2.47M derived: sum of 4 quarters · filed 2021-05-13 |
| 2020-03-31 | $2.47M 10-Q · filed 2021-05-13 | $2.47M derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30 | $15.23M 10-K · filed 2021-03-30 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $26.19M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $33.05M derived: sum of 4 quarters · filed 2020-08-10 |
| 2019-03-31 | $15.23M 10-Q · filed 2020-05-11 | $33.93M derived: sum of 4 quarters · filed 2020-05-11 |
| 2018-12-31 | $10.96M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $21.97M 10-K · filed 2020-03-16 |
| 2018-09-30 | $6.86M 10-Q · filed 2019-11-14 | $23.46M derived: sum of 4 quarters · filed 2019-11-14 |
| 2018-06-30 | $880.55K 10-Q · filed 2019-08-14 | $16.60M derived: sum of 4 quarters · filed 2019-08-14 |
| 2018-03-31 | $3.27M 10-Q · filed 2019-08-14 | $15.72M derived: sum of 4 quarters · filed 2019-08-14 |
| 2017-12-31 | $12.45M derived: 10-K 12 month − 10-Q 9 month · filed 2019-05-29 | $12.80M 10-K · filed 2019-05-29 |
| 2017-09-30 | $1.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | |
| 2017-03-31 | $347.36K 10-Q · filed 2017-05-10 | |
| 2016-09-30 | $4.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | |
| 2016-06-30 | $1.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | |
| 2016-03-31 | $149.28K 10-Q · filed 2016-05-10 | |
| 2015-09-30 | $3.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | |
| 2008-12-31 | $328.95K 10-K · filed 2013-03-27 | |
| 2007-03-31 | $212.00 10-K · filed 2013-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |